New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
08:55 EDTBIIBBiogen's TECFIDERA approved in the European Union
Biogen announced that TECFIDERA has been approved by the European Commission as a first-line oral treatment for people with relapsing-remitting multiple sclerosis. Biogen will begin to introduce TECFIDERA in initial European Union countries in the coming weeks. The EC approval is based on a clinical development program that included two global Phase 3 clinical trials, DEFINE and CONFIRM, as well as an ongoing extension study, ENDORSE, in which some patients have been followed for up to six and a half years. TECFIDERA has been clinically shown to "significantly" reduce important measures of disease activity, including relapses and the development of brain lesions, as well as to slow disability progression, while demonstrating a favorable safety and tolerability profile.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
07:52 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
07:21 EDTBIIBBiogen price target lowered to $400 from $425 at Credit Suisse
Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.
November 13, 2014
10:42 EDTBIIBSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
November 12, 2014
08:13 EDTBIIBBoston Biotech to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use